Molecular Imaging Able to Determine Effectiveness of Treatment for AI-Refractory, ER+ Advanced Breast Cancer

SCCA’s Hannah Linden, MD, discussed the use of molecular imaging to help clinicians predict responses to endocrine therapy for AI-refractory ER+ advanced breast cancer.

Read the Cancer Network Story